-
Olive Oil Polyphenols in Cardiovascular Protection
2026-08-18
The reference study compares standard and naturally high-phenolic extra virgin olive oil extracts with hydroxytyrosol and tyrosol across oxidative, inflammatory, and cholesterol-efflux assays. Its main contribution is showing that polyphenol concentration and chemical context can shape cardioprotective activity, while also identifying hydroxytyrosol as a particularly active experimental comparator.
-
Gepotidacin for Uncomplicated Urogenital Gonorrhea
2026-08-17
This phase 2 randomized study evaluated whether a single oral dose of the novel topoisomerase inhibitor gepotidacin could eradicate uncomplicated urogenital Neisseria gonorrhoeae infections. Both tested doses achieved at least 95% microbiological eradication in the evaluable population, supporting further development while highlighting the need to monitor susceptibility-associated mutations and assess broader anatomical and clinical populations.
-
Cinoxacin Workflows for Gram-Negative Research
2026-08-17
Cinoxacin supports practical susceptibility, bactericidal, and resistance-selection workflows centered on aerobic Gram-negative urinary pathogens. Its historical agar-dilution and disk-diffusion performance also provides a useful framework for connecting MIC measurements with applied urinary tract infection research.
-
Firefly Luciferase mRNA: Delivery and Assay Guide
2026-08-16
Build more reproducible reporter assays with Cap1-capped, 5-moUTP modified mRNA for sensitive translation, delivery, viability, and imaging studies. This practical guide connects transcript handling and transfection design with lipid nanoparticle process choices, including concentration, buffer, and storage variables.
-
Liproxstatin-1 Workflow for Ferroptosis Research
2026-08-15
Build more discriminating ferroptosis assays with Liproxstatin-1, a nanomolar small-molecule ferroptosis inhibitor that separates lipid-peroxidation-driven death from apoptosis and nonspecific oxidative injury. This practical guide covers dosing, BODIPY-based readouts, GPX4-deficient cell protection, renal injury models, and the membrane-remodeling insights of a recent Science Advances study.
-
Carbapenemase Gene Dynamics in CREC, Guangdong
2026-08-15
Chen et al. profiled 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong and combined gene localization, antimicrobial susceptibility, conjugation, mobile-element analysis, and ERIC-PCR typing. The high prevalence and transferability of blaNDM-1, together with multidrug resistance and interhospital genotypic overlap, highlight the need to monitor both plasmid-mediated and clonal dissemination.
-
Cinoxacin: From MIC to UTI Assay Design
2026-08-14
Cinoxacin is a quinolone antibiotic best understood through the relationship between susceptibility, bacterial killing, and urinary exposure. This assay-focused guide translates its spectrum, pharmacology, and historical comparative evidence into practical decisions for urinary tract infection research and antibiotic resistance studies.
-
Cefazedone Assay Design: From MIC to PK/PD
2026-08-14
Cefazedone (Refosporen) assay design requires more than a single MIC value. This guide connects broth-dilution methodology, resistant-isolate comparisons, β-lactamase interpretation, and free-drug PK/PD to build more reproducible antibacterial studies.
-
Ceftolozane sulfate: Assay and PK/PD Workflows
2026-08-13
Build more reproducible Gram-negative antibacterial studies with Ceftolozane sulfate, from MIC testing to time-kill and animal PK/PD experiments. This workflow emphasizes isolate stratification, AmpC stability, exposure-driven interpretation, and resistance-aware troubleshooting for Pseudomonas aeruginosa research.
-
Cinoxacin in Cell and Gram-Negative Assays
2026-08-13
Learn how Cinoxacin (SKU BA1045) can clarify antimicrobial effects in bacterial, host-cell, and coculture experiments without confusing bacterial suppression with mammalian cytotoxicity. The article provides scenario-based guidance on solvent controls, MIC interpretation, assay compatibility, and practical product selection.
-
ISG20 Atherosclerosis: From Causality to Imaging
2026-08-12
A translational framework for connecting genetic evidence, macrophage biology, plaque localization, and fluorescence detection using the HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody.
-
Amyloid Beta-peptide (25-35): Assay Design
2026-08-12
Amyloid Beta-peptide (25-35) is a focused tool for modeling mitochondrial stress, oxidative injury, aggregation, and microglial signaling. This guide presents a pathway-aware assay framework that connects Aβ25-35 exposure to the FLOT1–FOSL2–EphA2 axis without overstating what a short peptide model can represent.
-
CDK4/6–BET Synergy in Pancreatic Cancer
2026-08-11
Gu et al. show that palbociclib alone can restrain pancreatic tumor-cell growth while unexpectedly enhancing migration, invasion, and epithelial-to-mesenchymal transition. Their study identifies BET inhibition with JQ1 as a means of reversing this phenotype through coordinated regulation of GSK3β-mediated Wnt/β-catenin and TGF-β/Smad signaling.
-
Mupirocin and Novobiocin Activity in Canine Staphylococci
2026-08-10
Fulham and colleagues compared mupirocin and novobiocin susceptibility in meticillin-susceptible and meticillin-resistant staphylococci recovered from healthy dogs and dogs with superficial pyoderma. The study’s main contribution is its clinically relevant comparison of resistance groups and specimen populations, showing preserved mupirocin activity but more variable novobiocin susceptibility among resistant isolates.
-
LY2109761: Mapping TGF-β Signaling in Stemness
2026-08-09
LY2109761 is a TGF-β receptor type I and II dual inhibitor for dissecting receptor-proximal signaling, tumor plasticity, and fibrosis biology. This article translates mechanistic findings on Smad signaling and Sca-1 plasticity into practical assay and interpretation strategies.